NSCLC根治性放化疗后PET检出肺炎的识别模式及其对FDG-PET/CT疗效评估预测能力的影响
该回顾性分析纳入三项前瞻性试验中87例接受根治性放疗或放化疗的NSCLC患者,于放疗后约3个月行FDG-PET/CT。71%患者出现PET肺炎,其分级或分布模式与随访疗效及总生存无显著关联,但早期FDG-PET/CT疗效评估对总生存有预后价值。
要点
- 放疗后约3个月FDG-PET/CT常见PET肺炎(62/87,71%)。
- PET肺炎分级或模式与疗效及总生存无显著关联。
- 早期FDG-PET/CT疗效评估对总生存有预后价值。
核心结论
- PET肺炎在根治性放化疗或放疗后早期常见,但模式识别可辅助FDG-PET/CT疗效评估。
- PET肺炎不混淆早期疗效评估,也不独立预测总生存。
- 早期FDG-PET/CT疗效评估对总生存有预后价值。
研究设计与样本
- 回顾性分析三项前瞻性试验中87例NSCLC患者,接受根治性放疗7例或放化疗80例,均有基线与治疗后FDG-PET/CT。
- 治疗后FDG-PET/CT采用视觉标准进行疗效评估,PET肺炎按参考器官相对肺摄取强度以Deauville评分1-5级分级。
- PET肺炎分布模式定义为A)斑片/胸膜下;B)弥漫(累及超过一个肺段);C)外周(弥漫环绕无摄取区)。
主要发现
- 随访FDG-PET/CT于放疗后中位89天(四分位距79-93)进行。
- PET肺炎见于62/87(71%)患者,其中Deauville 2或3级12/62(19%),4或5级50/62(81%)。
- 模式A、B、C频率分别为19/62(31%)、20/62(32%)、23/62(37%)。
- PET肺炎分级或模式与随访PET/CT总体疗效无关联(p=0.27和p=0.56)。
- PET肺炎与总生存无显著关联(HR 1.3;95%CI 0.6-2.5;p=0.45);早期FDG-PET/CT疗效评估对总生存有预后价值(HR 1.7;95%CI 1.2-2.2;p<0.001)。
关键数值与推荐
- PET肺炎分级基于相对肺摄取强度对比参考器官,按Deauville评分1-5级。
- 分布模式A为斑片/胸膜下,B为弥漫累及超过一个肺段,C为外周弥漫环绕无摄取区。
- 疗效评估采用视觉标准。
临床怎么用
- 放疗后早期FDG-PET/CT评估疗效时,应识别PET肺炎的分布模式以辅助判读。
- PET肺炎常见但不应视为混淆早期疗效评估或独立预测总生存的因素。
- 早期FDG-PET/CT疗效评估可用于NSCLC根治性放化疗后的总生存预后判断。
局限性
- 回顾性分析设计。
- 样本量87例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS). METHODS: Retrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment FDG-PET/CT. Visual criteria were performed for post-treatment FDG-PET/CT response assessment. The grading of PET-pneumonitis was based on relative lung uptake intensity compared to organs of reference and classified as per Deauville score from grade 1-5. Distribution patterns of PET-pneumonitis were defined as follows: A) patchy/sub-pleural; B) diffuse (involving more than a segment); and C) peripheral (diffusely surrounding a photopenic region). RESULTS: Follow-up FDG-PET/CT scans were performed approximately 3 months (median, 89 days; interquartile range, 79-93) after RT. Overall, PET-pneumonitis was present in 62/87 (71%) of patients, with Deauville 2 or 3 in 12/62 (19%) and 4 or 5 in 50/62 (81%) of patients. The frequency of patterns A, B and C of PET-pneumonitis was 19/62 (31%), 20/62 (32%) and 23/62 (37%), respectively. No association was found between grade or pattern of PET-pneumonitis and overall response at follow-up PET/CT (p = 0.27 and p = 0.56, respectively). There was also no significant association between PET-pneumonitis and OS (hazard ratio [HR], 1.3; 95% confidence interval [CI], 0.6-2.5; p = 0.45). Early FDG-PET/CT response assessment, however, was prognostic for OS (HR, 1.7; 95% CI, 1.2-2.2; p < 0.001). CONCLUSION: PET-pneumonitis is common in early post-CRT/RT, but pattern recognition may assist in response assessment by FDG-PET/CT. While FDG-PET/CT is a powerful tool for response assessment and prognostication, PET-pneumonitis does not appear to confound early response assessment or to independently predict OS.
引用
- Iravani A, Turgeon GA, Akhurst T, et al. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. Eur J Nucl Med Mol Imaging. 2019. PMID: 31190177. doi:10.1007/s00259-019-04388-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。